# Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

- Source: PR Newswire
- Published: 2026-10-17T12:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/vivacta-bio-and-grit-bio-announce-fda-orphan-drug-designation-for-in-vivo-car-t-therapy-gt801-in-autoimmune-hemolytic-anemia-302911806.html
- Canonical: https://groundlevelnews.com/story/vivacta-bio-and-grit-bio-announce-fda-orphan-drug-designation-for-in-v-3c72d2/

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co., Ltd. ("Grit Bio"), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._